Jan 29 (Reuters) - SANTHERA PHARMACEUTICALS HOLDING AG :
* INCREASE OF 21% YOY IN FY NET REVENUES TO CHF 22.9 MILLION (2016: CHF 19.0 MILLION) FROM SALES OF RAXONE
* FOR 2017, SANTHERA ANTICIPATES A NET RESULT OF CHF -50 TO -55 MILLION.
* FOR 2018 EXPECTS NET SALES OF RAXONE FOR CURRENTLY APPROVED INDICATION LHON TO REACH CHF 28 TO 30 MILLION Source text for Eikon: Further company coverage: (Gdynia Newsroom)
 